|
|
Prenetics Global Limited (NASDAQ: PRE) |
|
Price: $24.0075
$0.54 
2.290%
|
| Day's High:
| $24.530000686645508
| Week Perf:
| -6.29 %
|
| Day's Low: |
$ 22.50 |
30 Day Perf: |
21.87 % |
| Volume (M): |
118,793 |
52 Wk High: |
$ 27.24 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$17.64 |
| Open: |
$22.78 |
52 Wk Low: |
$9.28 |
|
|
| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
350 |
| Revenues (TTM) (Millions $) |
92 |
| Net Income (TTM) (Millions $) |
-40 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Prenetics Global Limited is a Hong Kong-based company that specializes in DNA testing and digital health solutions. Founded in 2014, Prenetics aims to empower individuals to take control of their health by providing personalized and preventive healthcare services. The company offers a range of DNA testing services, such as genetic wellness and predisposition testing, which help individuals understand their risk factors for certain health conditions. Prenetics also offers digital health solutions, including remote patient monitoring and telehealth services, to improve healthcare accessibility and efficiency. With a mission to enhance the quality of life for individuals globally, Prenetics has expanded its operations to several countries including Hong Kong, Singapore, Malaysia, Thailand, and the United Kingdom.
Company Address: Unit 703-706, K11 Atelier Quarry Bay 0
Company Phone Number: 2210-9588 Stock Exchange / Ticker: NASDAQ PRE
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Product Service News
Published Tue, Sep 9 2025 7:38 AM UTC
In an era where sports and health intersect increasingly, Prenetics Global Limited (NASDAQ: PRE), a frontrunner in health sciences, finds itself in the spotlight, thanks to its celebrated global ambassador and shareholder World No. 1 tennis player Aryna Sabalenka. The company recently congratulated Sabalenka on her impressive feat: defending her singles at the 2025 US Open....
|
| Product Service News
Published Tue, Jan 21 2025 8:06 PM UTC
In an era where health and wellness trends are constantly evolving, Prenetics is making a bold statement with its latest offering, the IM8, a comprehensive health solution making its debut in the United States. Co-founded by soccer legend and global icon David Beckham, the IM8 aims to revolutionize how consumers approach their foundational health.The exciting launch, held in...
|
| Financing Agreement
Published Tue, Oct 15 2024 12:30 PM UTC
Prenetics Global Limited Strengthens Its Portfolio with Tencentns Investment in Insighta and Acquisition of Europa Sports PartnersIn a notable development in the healthcare and wellness sectors, Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, has announced a strategic investment from technology giant Tencent and the acquisition of sports nutrition...
|
| Merger and Acquisition
Published Mon, Aug 19 2024 12:30 PM UTC
In a significant move set to reshape the landscape of the sports nutrition market, Prenetics Global Limited (NASDAQ: PRE), a leading player in laboratory analytical instruments, has announced the acquisition of Europa Sports Partners. This partnership positions Prenetics to leverage Europa s vast distribution network of over 10,000 gyms across the United States, effecti...
|
| Partnership
Published Thu, Jul 11 2024 12:30 PM UTC
Prenetics Partners with David Beckham to Launch New Health and Wellness Brand LOS ANGELES, July 11, 2024 Prenetics (NASDAQ: PRE), a prominent company in the health sciences sector, has announced a strategic partnership with former international footballer David Beckham. Beckham, who is also recognized for his entrepreneurial efforts and philanthropy, has become a strateg...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
0 $ |
| Revenues (TTM) |
-
|
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
262,257 |
| Net
Income per Employee (TTM) |
-114,223 |
| Receivable Turnover Ratio (TTM) |
30.82 |
| Inventory Turnover Ratio (TTM) |
- |
| Asset Turnover Ratio (TTM) |
0.45 |
|
|
| Per Share |
|
| Earnings (TTM) |
0 $
|
| Revenues (TTM) |
- |
| Cash Flow (TTM) |
- |
| Cash |
-
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Goods transferred at a point in time |
|
 85.78 % |
of total Revenue |
| Services transferred at a point in time |
|
14.1 % |
of total Revenue |
| Services transferred overtime |
|
0.77 % |
of total Revenue |
| Prevention - genetic testing |
|
14.1 % |
of total Revenue |
| Consumer health - health and wellness solutions |
|
65.53 % |
of total Revenue |
| Consumer health - sports distribution |
|
21.02 % |
of total Revenue |
| Prevention |
|
14.1 % |
of total Revenue |
| Prevention segments |
|
14.1 % |
of total Revenue |
| Consumer Health segments |
|
86.55 % |
of total Revenue |
| Hong Kong |
|
25.13 % |
of total Revenue |
| The United States |
|
75.52 % |
of total Revenue |
| Discontinued operations |
|
10.46 % |
of total Revenue |
| Discontinued operations Hong Kong |
|
2.61 % |
of total Revenue |
| Discontinued operations United Kingdom |
|
1.96 % |
of total Revenue |
| Discontinued operations Taiwan |
|
5.27 % |
of total Revenue |
| Discontinued operations Rest of the world |
|
0.63 % |
of total Revenue |
| Discontinued operations Services transferred at a point in time |
|
10.46 % |
of total Revenue |
| Discontinued operations Diagnostics - sale of precision oncology services |
|
10.46 % |
of total Revenue |
| Discontinued operations Prevention and Diagnostics |
|
10.46 % |
of total Revenue |
| Discontinued operations ACT genomics |
|
10.46 % |
of total Revenue |
| Discontinued operations ACT genomics Hong Kong |
|
2.61 % |
of total Revenue |
| Discontinued operations ACT genomics United Kingdom |
|
1.96 % |
of total Revenue |
| Discontinued operations ACT genomics Taiwan |
|
5.27 % |
of total Revenue |
| Discontinued operations ACT genomics Rest of the world |
|
0.63 % |
of total Revenue |
| Discontinued operations ACT genomics Services transferred at a point in time |
|
10.46 % |
of total Revenue |
| |
On March 5 2025 the Prenetics Global Limited provided following guidance
nnPrenetics Global Limited Financial Performance and 2025 Outlooknn
Prenetics Global Limited has recently released its financial results for the fourth quarter and full year of 2024, showcasing impressive growth figures. In the fourth quarter, the company's revenue surged by an astonishing nn93.5%nn, reaching nn$10.5 millionnn. This remarkable performance continues to reflect a strong upward trajectory for the organization as it also reported a year-over-year revenue increase of nn40.9%nn, culminating in a total of nn$30.6 millionnn for the entire fiscal year of 2024.
While the company has announced these significant financial achievements, it has not specified detailed financial guidance f...
|
|
|
2.57%